DLA Piper advises Mérieux Equity Partners on its acquisition of a significant minority stake in Health in Code

DLA Piper has advised Mérieux Equity Partners (MxEP) on its investment in Health in Code (HiC), Spain’s leading integrated clinical genetics platform, alongside Alantra Private Equity’s continuation vehicle and Management.

MxEP is making the investment through its buyout fund, Mérieux Participations 4 (MP4), to support and accelerate HiC’s next phase of growth and international expansion.

Founded in 2020 through the strategic combination of Health in Code, Imegen, Genycell Biotech, and later Genologica, HiC has become a leading player in genetic diagnostics and precision medicine. Headquartered in Valencia, Spain, the company has built an integrated model combining Next-Generation Sequencing (NGS)-based diagnostic services, genetic testing kits and panels, and proprietary bioinformatics and clinical interpretation.

Under Alantra Private Equity’s ownership, HiC has more than doubled its revenues from EUR24 million to more than EUR50 million, consolidated its leadership in the domestic market and scaled operations to approximately 200 employees, supporting healthcare professionals in more than 30 countries.

DLA Piper advised Mérieux Equity Partners on the legal aspects of the transaction.

DLA Piper advised Mérieux Equity Partners on the corporate aspects of the transaction with:

In France: Sarmad Haidar, Partner, Jean Senard, Counsel and Loïc Bustos, associate.

In Spain: Joaquín Echánove, Partner, Luis Borrero Zorita, Counsel and Jorge Rahona Toledo, Associate.